## **Core Concept**
The patient's symptoms of frequent urination, suprapubic pain, dysuria, and hematuria following chemotherapy suggest a diagnosis of hemorrhagic cystitis, a known side effect of certain chemotherapeutic agents. This condition is often associated with **cyclophosphamide** and **ifosfamide**, which are alkylating agents used in the treatment of various cancers, including breast cancer.

## **Why the Correct Answer is Right**
The correct answer involves the use of a protective agent that can prevent or reduce the incidence of hemorrhagic cystitis caused by certain chemotherapeutic agents. **Mesna (sodium 2-sulfanylethanesulfonate)** is a uroprotective agent used to prevent hemorrhagic cystitis induced by ifosfamide and cyclophosphamide. It works by binding to the toxic metabolites of these drugs in the urine, thereby preventing their contact with the bladder mucosa and subsequent damage.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not correspond with a known preventive measure for hemorrhagic cystitis.
- **Option B:** Similarly, this option does not represent a recognized method for preventing the condition described.
- **Option C:** Not applicable as the correct answer is specified.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **mesna** is specifically used to prevent hemorrhagic cystitis in patients receiving **ifosfamide** or **cyclophosphamide**. This is a critical consideration in the management of patients undergoing chemotherapy with these agents, as it can significantly improve their quality of life by preventing a painful and potentially serious side effect.

## **Correct Answer:** . Mesna